Press Releases

- Distinguished Career at the U.S. Food and Drug Administration in CDER and the Office of Women's Health; Significant Industry and Regulatory Expertise -

- Assigns PDUFA Goal Date of May 25, 2020 -

- AMPREVENCE Study Met Primary and Secondary Endpoints - a 50% Relative Risk Reduction in Chlamydia Infection and a 78% Relative Risk Reduction in Gonorrhea Infection Compared to Placebo -

- Submission Supported by Phase 3 AMPOWER Data -

- San Diego Business Journal Recognizes the City's Top 15 Female Business Leaders -